We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

36 hedge funds and large institutions have $18.1M invested in Regulus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

90% more capital invested

Capital invested by funds: $9.54M → $18.1M (+$8.54M)

2.09% more ownership

Funds ownership: 2.07% → 4.16% (+2.1%)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

3% less funds holding

Funds holding: 37 → 36 (-1)

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
15
Reduced
5
Closed
3
Calls
$195K
Puts
–
Net Calls
+$195K
Net Calls Change
+$126K

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$7.56M
2
NMC
NEA Management Company
Maryland
+$2.08M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$169K
4
Renaissance Technologies
Renaissance Technologies
New York
+$28.9K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$17.1K

Top Sellers

Rank Fund Capital Flow
1
EAM
Empery Asset Management
New York
-$1.6M
2
Morgan Stanley
Morgan Stanley
New York
-$2K
3
GFS
GYL Financial Synergies
Connecticut
-$1.82K
4
Group One Trading
Group One Trading
Illinois
-$1.64K
5
Creative Planning
Creative Planning
Kansas
-$572

RGLS Hedge Fund Activity: Q1 2022 in Review

36 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2022, worth a combined $18.1M — up 90% from $9.54M a quarter earlier.

Fund positioning in RGLS was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 15 added to existing stakes and 5 trimmed.

The largest buyer was Federated Hermes, opening a new position worth an estimated $7.56M. The largest seller was Empery Asset Management, exiting entirely with an estimated $1.6M sold.

  • 36 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2022, down from 37 in Q4 2021.
  • Funds reported $18.1M of Regulus Therapeutics stock for Q1 2022, up 90% quarter-over-quarter.
  • 3 funds opened new Regulus Therapeutics positions in Q1 2022 and 3 closed out, a net change of 0 holders.
  • The largest Regulus Therapeutics buyer in Q1 2022 was Federated Hermes, an estimated $7.56M added.
  • The largest Regulus Therapeutics seller in Q1 2022 was Empery Asset Management, an estimated $1.6M sold.

Based on aggregated 13F filings for Q1 2022.